Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up

Inhibitors of Bruton’s tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients with WM who were either treatment-naïve (TN) or had relapsed/refr...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Trotman, Judith, Opat, Stephen, Gottlieb, David, Simpson, David, Marlton, Paula, Cull, Gavin, Munoz, Javier, Tedeschi, Alessandra, Roberts, Andrew W., Seymour, John F., Atwal, Siminder Kaur, Yu, Yiling, Novotny, William, Holmgren, Eric, Tan, Ziwen, Hilger, James D., Huang, Jane, Tam, Constantine S.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2020
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596846/
https://ncbi.nlm.nih.gov/pubmed/32698195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006449
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky